Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. Glaukos Corporation markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. The company was founded in 1998 and is headquartered in San Clemente, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:GKOS
CUSIPN/A
Phone949-367-9600
Debt
Debt-to-Equity RatioN/A
Current Ratio7.91
Quick Ratio7.22
Price-To-Earnings
Trailing P/E Ratio890.20
Forward P/E Ratio-102.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$159.25 million
Price / Sales8.96
Cash Flow$0.1437 per share
Price / Cash284.49
Book Value$4.00 per share
Price / Book10.22
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-90,000.00
Net Margins-2.25%
Return on Equity1.22%
Return on Assets1.05%
Miscellaneous
Employees387
Outstanding Shares34,910,000
Glaukos (NYSE:GKOS) Frequently Asked Questions
What is Glaukos' stock symbol?
Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos' earnings last quarter?
Glaukos Corp (NYSE:GKOS) posted its earnings results on Wednesday, May, 9th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The medical instruments supplier had revenue of $40.10 million for the quarter, compared to the consensus estimate of $37.63 million. Glaukos had a positive return on equity of 1.22% and a negative net margin of 2.25%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.02 EPS. View Glaukos' Earnings History.
When is Glaukos' next earnings date?
What price target have analysts set for GKOS?
9 analysts have issued 12-month price targets for Glaukos' shares. Their predictions range from $32.00 to $54.00. On average, they expect Glaukos' share price to reach $41.1429 in the next twelve months. View Analyst Ratings for Glaukos.
What are Wall Street analysts saying about Glaukos stock?
Here are some recent quotes from research analysts about Glaukos stock:
- 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (5/10/2018)
- 2. Cantor Fitzgerald analysts commented, "Executing Well in a Slightly Adverse Environment. Glaukos reported 37% YoY revenue growth, falling a little short of the 40%+ growth since the launch of iStent slightly more than four years ago (88% of the sales were recorded in the U.S.). The company reported to be on track to have trained >3,000 surgeons by YE17. Glaukos operated in an environment, which was affected by a number of factors: 1: the slow institution of higher reimbursement (challenging during implementation, but favorable afterwards) by commercial payors (20% of total); 2: hurricane-caused delays in surgery ($1 million impact in 3Q17); 3: a negative impact by a single Medicare operator (lowering surgeon’s fees) and by continued sampling and perhaps early sales by competitor Alcon (wholly owned by NVS [Not Covered]). Long term, we believe Glaukos’ iStent has demonstrated significant long-term benefit and cost efficiency to maintain a commercial and competitive advantage. The company remained cautious about 2018, due to the expanded launch by Alcon, a second competitor potentially arriving to the market by 2H18 (Hydrus by Ivantis [private]) and the relatively modest contribution by iStent Inject (PMA to be submitted by YE17). 2018 guidance will be introduced in January at the 4Q17 earnings call." (11/7/2017)
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include ICU Medical (ICUI), Hill-Rom (HRC), Insulet (PODD), Globus Medical (GMED), Penumbra (PEN), Haemonetics (HAE), Cantel Medical (CMD), NuVasive (NUVA), Novocure (NVCR), Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Luminex (LMNX) and Orthofix International (OFIX).
Who are Glaukos' key executives?
Glaukos' management team includes the folowing people:
- Mr. Thomas William Burns, CEO, Pres & Director (Age 57)
- Mr. Chris M. Calcaterra, Chief Operating Officer (Age 58)
- Mr. Richard L. Harrison, Advisor (Age 61)
- Dr. Mory Gharib Ph.D., Co-Founder
- Mr. Joseph E. Gilliam, CFO & Sr. VP - Corp. Devel.
When did Glaukos IPO?
(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Has Glaukos been receiving favorable news coverage?
News coverage about GKOS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Glaukos earned a coverage optimism score of 0.03 on Accern's scale. They also gave news headlines about the medical instruments supplier an impact score of 46.20 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Glaukos' major shareholders?
Glaukos' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.75%), Baillie Gifford & Co. (3.21%), Federated Investors Inc. PA (2.27%), Cortina Asset Management LLC (1.92%), Granite Investment Partners LLC (1.27%) and Artisan Partners Limited Partnership (1.22%). Company insiders that own Glaukos stock include Chris M Calcaterra, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.
Which institutional investors are selling Glaukos stock?
GKOS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Wells Fargo & Company MN, GSA Capital Partners LLP, Artisan Partners Limited Partnership, JPMorgan Chase & Co., C WorldWide Group Holding A S, Koch Industries Inc. and Russell Investments Group Ltd.. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc and Thomas William Burns. View Insider Buying and Selling for Glaukos.
Which institutional investors are buying Glaukos stock?
GKOS stock was acquired by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Granite Investment Partners LLC, Federated Investors Inc. PA, State of Wisconsin Investment Board, Baillie Gifford & Co., Prudential Financial Inc., Amundi Pioneer Asset Management Inc. and Handelsbanken Fonder AB. View Insider Buying and Selling for Glaukos.
How do I buy shares of Glaukos?
Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Glaukos' stock price today?
One share of GKOS stock can currently be purchased for approximately $40.88.
How big of a company is Glaukos?
Glaukos has a market capitalization of $1.55 billion and generates $159.25 million in revenue each year. Glaukos employs 387 workers across the globe.
How can I contact Glaukos?
Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]
MarketBeat Community Rating for Glaukos (GKOS)
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
